Nafiye Fulya İLHAN, Nesrin DEMİR, Tamer DEMİR, Ahmet GÖDEKMERDAN

Serum osteoprotegerin (OPG) measurement in Behçet's disease

Recent studies indicate that osteoprotegerin (OPG) acts as an important molecule in the development of vascular diseases. The aim of the present study was to examine the association between serum OPG levels and Behcet's disease (BD). Materials and methods: Twenty-five patients with BD and 20 healthy control subjects, matched for age and sex, were included in this study. Serum levels of OPG were determined using ELISA. Results: We found that serum levels of OPG were significantly higher in patients with BD than in healthy control subjects (813.75 ± 11 vs. 655.56 ± 17 pg/mL, P = 0.002). There was no difference between active patients and those in remission. Conclusion: Collectively, serum OPG levels were increased in BD patients, suggesting that OPG might be linked with the development of vasculitis or other inflammatory processes. It was determined that OPG cannot be used as a monitoring test by itself; however, it might be a useful marker for supporting clinical and laboratory findings in relation with BD. Further detailed studies are necessary for a more definitive evaluation of these results.

Anahtar Kelimeler:

Key words: Behçet's disease, osteoprotegerin

Serum osteoprotegerin (OPG) measurement in Behçet's disease

Keywords:

Key words: Behçet's disease, osteoprotegerin,

PDF

___

1. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through OPG ligand. Nature 1999; 402: 304- 09.
2. Anderson MA, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendriticcell function. Nature 1997; 390: 175-79.
3. Kurban S, Mehmetoğlu I. OPG, Rank and Rank Ligand. Turk J Biochem 2007; 32: 178-84.
4. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA and Giachelli CM. OPG is an αv β3-induced, NF-kB-dependentsurvival factor for endothelial cells. J Biol Chem 2000; 275: 20959-962.
5. Hofb auer LC, Schoppety M, Christz M, Teichmann J, Lange U. Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis. Rheumatology 2006; 45: 1218-222.
6. Lub-de Hooge MN, de Vries EG, de Jong S, Bijl M. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 854-58.